Compare IART & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | SYRE |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1995 | 2016 |
| Metric | IART | SYRE |
|---|---|---|
| Price | $13.23 | $33.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $15.00 | ★ $55.50 |
| AVG Volume (30 Days) | ★ 874.9K | 652.6K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,642,966,000.00 | N/A |
| Revenue This Year | $3.26 | N/A |
| Revenue Next Year | $2.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.99 | N/A |
| 52 Week Low | $10.87 | $10.91 |
| 52 Week High | $27.13 | $34.54 |
| Indicator | IART | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 78.25 |
| Support Level | $12.81 | $28.16 |
| Resistance Level | $13.43 | $34.54 |
| Average True Range (ATR) | 0.57 | 1.94 |
| MACD | 0.24 | 0.70 |
| Stochastic Oscillator | 78.69 | 92.54 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.